HC Wainwright Reaffirms Buy Rating for Cynata Therapeutic (CYYNF)
September 12th, 2017
By Renee Jackson - 0 comments
HC Wainwright restated their buy rating on shares of Cynata Therapeutic (OTC:CYYNF) in a report issued on Friday.
Cynata Therapeutic (OTC:CYYNF) opened at 0.445 on Friday. Cynata Therapeutic has a 52-week low of $0.34 and a 52-week high of $0.50. The firm’s market cap is $40.08 million.
WARNING: “HC Wainwright Reaffirms Buy Rating for Cynata Therapeutic (CYYNF)” was posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this piece on another site, it was illegally stolen and republished in violation of international trademark & copyright legislation. The original version of this piece can be viewed at https://www.thecerbatgem.com/2017/09/12/hc-wainwright-reaffirms-buy-rating-for-cynata-therapeutic-cyynf.html.
Receive News & Stock Ratings for Cynata Therapeutic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cynata Therapeutic and related stocks with our FREE daily email newsletter.